

A multi-stakeholder partnership initiative

10 February 2012







European Society for Medical Oncology



European Society for Medical Oncology (ESMO) Rare Tumors in Europe: Challenges and Solutions 6 November 2008 - Hotel Renaissance, Brussels

39 recommendations on stakeholder actions and public policies:

- » 8 addressing <u>regulatory</u> <u>barriers in rare cancer care</u>
- » 6 addressing <u>methodological</u> <u>barriers</u> to rare cancer care
- 9 addressing the <u>need for</u> <u>centres of expertise and</u> <u>European reference networks</u>

- » 11 addressing <u>barriers to</u> <u>patients' access to care</u>
- » 2 on <u>education of healthcare</u> professionals
- » 3 on access to information on rare cancers

Rare Cancers Europe Cooperating Organisations





Goals and Strategy





Goal 1



Goal 1

Activities

- 1. 2011-2012: Consensus disc. and conference / consensus meeting on the methodology of clinical research on rare cancers (oncologists, biostatisticians, researchers, regulators, nurses, patient advocacy groups, ...)
- 2. 2012: Advocacy activities (EU & MS regulatory authorities)

Deliverables

- 1. Conference / consensus meeting (9/10 February 2012) and pre-document
- 2. Scientific meeting report / consensus paper
- 3. Publication of report / paper (Annals of Oncology or else)
- 4. Set of advocacy materials for national adaptation

Measures of success

- 1. Publication of meeting report / consensus paper
- 2. Number of studies by cooperative groups and pharma industry after 5 years and number of patients recruited
- 3. Changes in the clinical trials environment

Improve the methodology of clinical research on rare cancers



Goal 2



Goal 2

Activities

- 1. 2011-2012: European rare cancer-related surveys on collaborative networks and EU National plans and on existing Clinical Guidelines
- 2. 2012: 2 meetings to develop consensus guidelines (TBD)
- 3. 2012: Advocacy activities with network leaders for guideline implementation

Deliverables

- 1. Publication of survey results (Annals of Oncology or else)
- 2. Consensus guidelines for quality criteria of collab. networks on health care of rare cancer patients
- 3. Documentation of exist. Clin. Practice Guidelines on one or more rare cancers in Europe
- 4. Set of advocacy materials

Measures of success

- 1. Publication of survey results
- 2. Publication of consensus guidelines for quality criteria
- 3. Implementation of consensus guidelines and development of new CPGL for rare cancers
 - * Research institutes / patient organisations responsible for project management, funding, surveys, and results analysis. I n collaboration with EPAAC WP7 (sarcomas) and RARECARENet (CPGL).

Improve the organisation of health care in rare cancers



Goal 3



Goal 3		
Activities 1. 2011/2012: Development of "Horizontal" index measuring access to rare cancer treatment and care in EU 27 2. 2012: Comparative multi- stakeholder case studies (text and multi-media) 3. 2012: Initial Conference (TBD) 4. Rare cancer med. edu. events Improve access of rate	 Deliverables 1. Access Index and scientific report 2. Series of 3 comparative text and multi-media case studies (2 countries per case study) and related template materials 3. Campaign/advocacy materials for national adaptation 4. Rare cancer events/sessions 	 Measures of success Participation of all EU 27 Member States Publication of scientific report (Annals of Oncology, Cancer World or else) Availability of at least 3 case studies by end 2012 At least 4 events/sessions p.a. (incl. EP/political edu. events)





More Information



www.rarecancers.eu

Sign the Call to Action Against Rare Cancers